Prevalence of Osteoporosis in Patients Who Uses Inhaled Steroids

Osteoporosis Clinical Trial

Official title:

Prevalence of Osteoporosis in Patients Who Uses Inhaled Steroids

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT01246375
• Other study ID #: TASMC-10-SY-454-CTIL
• Status: Not yet recruiting
• Phase: N/A
• First received: November 21, 2010
• Last updated: November 24, 2010
• Start date: December 2010
• Est. completion date: December 2011

Study information

• Verified date: November 2010
• Source: Tel-Aviv Sourasky Medical Center
• Contact: Eitan Segal, B.Sc
• Phone: 97236947507
• Email: eitansegal2[@]gmail.com
• Is FDA regulated: No
• Health authority: Israel: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

The purpose of this research is to determine whether the prevalence of osteoporosis is greater in patients who suffer from Chronic obstructive pulmonary disease (COPD) or Asthma disease and uses inhaled steroids.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 20
• Est. completion date: December 2011
• Est. primary completion date: December 2011
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 60 Years to 90 Years

Eligibility

Inclusion Criteria:

1. Man at the minimum age of 60 years.

2. Diagnosed with Chronic Obstructive Pulmonary disease (COPD) or Asthma disease.

3. Usage of the following corticosteroids at the minimal doses indicated, for at least 3 years:

Seretide 250/50 mcg Symbicort 320/9 mcg 5.No Diagnosis of thyroid irregularity 6.No diagnosis/treatment for Osteoporosis.

Exclusion Criteria:

1. Usage of systemic steroids more than once during the 12 months prior to the study.

2. Usage of systemic steroids during the month prior to the study.

3. Usage of inhaled steroids in order to treat any other disease except Chronic Obstructive Pulmonary Disease (COPD) or Asthma.

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Osteoporosis

Intervention

Device:
• Dual energy X-ray absorptiometry
Device which measures bone density

Locations

Country	Name	City	State
Israel	Tel Aviv medical center	Tel Aviv

Sponsors (1)

Lead Sponsor	Collaborator
Tel-Aviv Sourasky Medical Center

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Diagnosis of Osteoporosis		3 month	No
Primary	Diagnosis of Osteoporosis		3	No